Renin-angiotensin system antagonism and lipid-lowering therapy in cardiovascular risk management

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 3, Issue 2, 2002, Pages 96-102

  Chiong, Jun R ^a   Miller, Alan B ^a  

^a UNIVERSITY OF FLORIDA HEALTH SCIENCE CENTER   (United States)

Author keywords

Angiotensin receptor blockers; Angiotensin converting enzyme inhibitors; Atherosclerosis; Renin angiotensin system; Statins

Indexed keywords

ANTIHYPERTENSIVE AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ANGIOTENSIN; ANGIOTENSIN I; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; IRBESARTAN; LISINOPRIL; LOSARTAN; PRAVASTATIN; QUINAPRIL; RAMIPRIL; SIMVASTATIN;

CARDIOVASCULAR DISEASE; DRUG EFFECT; HUMAN; HYPERLIPIDEMIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK MANAGEMENT; ANGIONEUROTIC EDEMA; ANTIHYPERTENSIVE ACTIVITY; CARDIOVASCULAR RISK; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; COUGHING; DISEASE ASSOCIATION; DISEASE COURSE; DRUG CLASSIFICATION; DRUG MECHANISM; DYSLIPIDEMIA; HYPERTENSION; PATHOPHYSIOLOGY;

ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; RENIN-ANGIOTENSIN SYSTEM; RISK MANAGEMENT; HUMAN; HYPERLIPIDEMIA;

EID: 0036615538     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2002.024     Document Type: Review

References (103)

1. Use of angiotensin II receptor blockers in animal models of atherosclerosis
2. Relationship of blood pressure, serum cholesterol, smoking habit, relative weight and ECG abnormalities to incidence of major coronary events: Final report of the pooling project
3. Cardiovascular morbidity in relation to change in blood pressure and serum cholesterol levels in treated hypertension. Results from the primary prevention trial in Goteborg, Sweden
4. Endothelial dysfunction in atherosclerosis
5. Tissue angiotensin system in cardiovascular medicine. A paradigm shift?
6. Implications of local angiotensin production in cardiovascular physiology and pharmacology
7. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease
8. Pathobiology of atherosclerosis and plaque complications
9. Modulation of oxidant stress in vivo in chronic cigarette smokers
10. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease
11. Influence of plasma lipoprotein (a) levels on coronary vasomotor response to acetylcholine
12. The role of endothelium in cardiovascular homeostasis and diseases
13. Cloning, expression and regulation of angiotensin II receptors
14. Angiotensin II-stimulated protein synthesis in cultured vascular smooth muscle cells
15. Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall
16. Angiotensin II related to sodium excretion modulates left ventricular structure in human essential hypertension
17. Plasma angiotensin II, predisposition to hypertension, and left ventricular size in healthy young adults
18. Angiotensin II stimulates left ventricular hypertrophy in hypertensive patients independently of blood pressure
19. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury
20. Evidence that macrophages in atherosclerotic lesions contain angiotensin II
21. Macrophage-mediated oxidation of extracellular low density lipoprotein requires an initial binding of the lipoprotein to its receptor
22. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
23. Modified lipoproteins in diabetes
24. Proapoptotic effects of ANG II in human coronary artery endothelial cells: Role of AT1 receptor and PKC activation
25. The oxidative modification hypothesis of atherogenesis: An overview
26. Putting low-density lipoproteins at center stage in atherogenesis
27. Modified forms of low density lipoprotein and atherosclerosis
28. Susceptibility to low-density lipoprotein oxidation and coronary atherosclerosis in man
29. 1-receptor expression
30. The pathogenesis of atherosclerosis: A perspective for the 1990's
31. Lipoprotein metabolism
32. Lipoprotein trafficking in vascular cells. Molecular Trojan horses and cellular saboteurs
33. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells
34. L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans
35. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors
36. Incidence of coronary heart disease and lipoprotein cholesterol levels
37. Downregulation of angiotensin II type 1 receptor by hydrophobic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in vascular smooth muscle cells
38. Upregulation of endothelial receptor for oxidized low-density lipoprotein (LOX-1) in cultured human coronary artery endothelial cells by angiotensin II type 1 receptor activation
39. Angiotensin II induces LOX-1, the human endothelial receptor for oxidized low-density lipoprotein
40. Vascular smooth muscle cell hypertrophy vs. hyperplasia. Autocrine transforming growth factor-beta 1 expression determines growth response to angiotensin II
41. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions
42. Effects of captopril on ischemic events after myocardial infarction
43. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial
44. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction
45. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure
46. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction
47. Ramipril prevents impaired endothelium-dependent relaxation in arteries from rabbits fed an atherogenic diet
48. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease
49. Lisinopril improves arterial function in hyperlipidaemia
50. Effect of enalaprilat on nitric oxide activity in coronary artery disease
51. Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study)
52. Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit
53. Tissue angiotensin and pathobiology of vascular disease
54. Inhibition of angiotensin converting enzyme (ACE) in plasma and tissues: Studies ex vivo after administration of ACE inhibitors
55. Effects of ramipril and vitamin E on atherosclerosis: The study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE)
56. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy
57. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril
58. Does blockade of angiotensin II receptors offer clinical benefits over inhibition of angiotensin-converting enzyme?
59. AT1 receptor blockade in experimental myocardial ischemia/reperfusion
60. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension
61. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: A comparative study of the efficacy and safety against amlodipine
62. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: Efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril
63. Valsartan, a new angiotensin II receptor antagonist: A double-blind study comparing the incidence of cough with lisinopril and hydrochlorothiazide
64. Double-blind comparison of eprosartan and enalapril on cough and blood pressure in unselected hypertensive patients
65. Effects and tolerability of irbesartan versus enalapril in patients with severe hypertension
66. Angiotensin II type 1 (AT1) receptor blockade in hypertensive women: Benefits of candesartan cilexetil versus enalapril or hydrochlorothiazide
67. Once-daily telmisartan compared with enalapril in the treatment of hypertension
68. Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors
69. Bradykinin-induced cough reflex markedly increases in patients with cough associated with captopril and enalapril
70. Plasma bradykinin in angio-oedema
71. Angiotensin type 1 receptor antagonism reverses abnormal coronary vasomotion in atherosclerosis
72. Irbesartan, an angiotensin type 1 receptor inhibitor, regulates markers of inflammation in patients with premature atherosclerosis
73. Upregulation of LOX-1 expression in aorta of hypercholesterolemic rabbits: Modulation by losartan
74. Blockade of angiotensin signaling improves myocardial function in hypercholesterolemia independent of changes in eicosanoid release
75. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan
76. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol
77. Candesartan in heart failure-assessment of reduction in mortality and morbidity (CHARM): Rationale and design
78. Valsartan in acute myocardial infarction trial (VALIANT): Rationale and design
79. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial-the Losartan Heart Failure Survival Study ELITE II
80. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure
81. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
82. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
83. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
84. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
85. Preservation of endogenous antioxidant activity and inhibition of lipid peroxidation as common mechanisms of antiatherosclerotic effects of vitamin E, lovastatin and amlodipine
86. Pulse pressure: A predictor of long-term cardiovascular mortality in a French male population
87. NO activity in familial combined hyperlipidemia: Potential role of cholesterol remnants
88. Responses to endothelium-dependent agonists in subcutaneous arteries excised from hypercholesterolaemic men
89. Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication
90. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month
91. Withdrawal of statins increases event rates in patients with acute coronary syndromes
92. Rationale and design of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study that evaluates atorvastatin in unstable angina pectoris and in non-Q-wave acute myocardial infarction
93. New National Cholesterol Education Program III guidelines for primary prevention lipid-lowering drug therapy: Projected impact on the size, sex, and age distribution of the treatment-eligible population
94. Angiotensin, LDL peroxidation and atherosclerosis
95. Oxidation of low-density lipoprotein in normotensive type 2 diabetic patients. Comparative effects of enalapril versus nifedipine: A randomized cross-over study
96. Effect of the angiotensin II receptor antagonist valsartan on lipid profile and glucose metabolism in patients with hypertension
97. Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril)
98. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
99. Effect of lovastatin on cardiovascular resource utilization and costs in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)
100. Clinical Trials: New findings from completed studies and future directions
101. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
102. Rationale, design, and baseline characteristics of a trial of prevention of cardiovascular and renal disease with fosinopril and pravastatin in nonhypertensive, nonhypercholesterolemic subjects with microalbuminuria of REnal and Vascular ENdstage Disease Intervention Trial [PREVEND IT])